GALT

$3.13-0.05 (-1.57%)

Market OpenAs of Mar 17, 6:58 PM UTC

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.13
Potential Upside
5%
Whystock Fair Value$3.29
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 i...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$201.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.08

Recent News

MarketBeat
Mar 17, 2026

Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps

Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, a population the speakers described as having substantial un

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 22, 2026

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders

Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Dec 19, 2025

Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line

Galectin Therapeutics (GALT) said Friday the US Food and Drug Administration provided a written resp

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Sep 23, 2025

Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Galectin Therapeutics Inc. is one of them. Galectin Therapeutics Inc. (NASDAQ:GALT) is a biopharmaceutical company developing therapies targeting galectin proteins, with its lead candidate, belapectin, focused on chronic liver diseases such as MASH cirrhosis […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Aug 15, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insiders

NasdaqCM:GALT 1 Year Share Price vs Fair Value Explore Galectin Therapeutics's Fair Values from the Community and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.